Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-626 in COVID-19 with Early Acute Kidney Injury
NCT05038488Phase 2Completed
- Sponsor
- Metro International Biotech
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute kidney injury (AKI) comparing MIB-626 with Placebo (2 arms). Primary endpoint: Change from baseline in serum cystatin C at 14 days. Started Oct 2021; status: completed.
02
Drugs
liposomal β-nicotinamide mononucleotide
03
Conditions
coronavirus disease 2019 (COVID-19)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05038488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038488.